Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies, in particular in world-class drug discovery & development as well as med tech companies addressing substantial unmet medical needs.
Crédit Agricole Private Equity is an AMF-accredited asset-management subsidiary of Crédit Agricole S.A. Its 12-strong Venture Capital team manages €400 million invested in young companies with high growth potential in the technology and life-sciences sectors.
OrbiMed Advisors LLC is a leading investment firm dedicated exclusively to the healthcare sector, with over $5 billion in assets under management. OrbiMed invests across the entire spectrum of healthcare companies on a worldwide basis. Investments are made through private equity funds, hedge funds, royalty funds, and other investment vehicles.
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies with offices in Amsterdam, Munich and Boston.
Seventure Partners is one of the leading venture capital firms in Europe, Seventure manages €500m and invests since 1997 in innovative businesses with high growth potential in Information & Communication Technologies and in Life Sciences.
The Erasmus MC Biomedical Fund is an independent venture capital fund targets companies that are developing commercially promising products and technologies in life sciences.
Thuja Capital is the manager of Thuja Capital Healthcare Fund, a venture capital fund dedicated to life science investments.
KBC Private Equity is the investment company of KBC Group, with a Life Sciences Venture Capital division targeting innovative medical biotech companies.
BioGeneration Ventures is a venture capital fund founded by NGI/NWO that invests in early stage companies in the Life Sciences in the Netherlands.
VIB is a non-profit research institute in life sciences. Through a close partnership with four Flemish universities − UGent, K.U.Leuven, University of Antwerp, and Vrije Universiteit Brussel − and a solid funding program, VIB unites the forces of 70 research groups in a single institute. Through its technology transfer activities, VIB strives to convert the research results into products for the benefit of consumers and patients.